Among the 82 patients with HER2-positive breast cancer, 11 did not receive anti-HER2-targeted therapy after BM diagnosis, while 68 patients did receive such treatment; information on 3 additional patients regarding subsequent anti-HER2-targeted therapy was missing. The gene discussed is ERBB2; the disease is breast carcinoma.